graham hughes - beta technology - fp 7 call presentation

Technology Strategy BoardDriving Innovation

FP7 2012 Health CallOverview

Graham Hughes, FP7UK NCP for Health (Industry)


“FP7 work programmes will “continue to secure world excellence in basic research” through large scale

collaborative research efforts

JM Barroso 2009


FP7 - €53 billion spend 2007 - 2013


Cooperation Theme


Cooperation Theme Basics

• Top down process, yearly call for proposals based around specific topic areas

• Projects performed by consortia of academic/industry/ public sector participants

• Matched funding (EU contributes to total cost of project)• Participants sign legal contract with the EU


Three Major Objectives

•Improve the health of European citizens

•Boost the competitiveness of health related industries

•Address global health issues

Also seeking to implement research objectives that help to realise the aims of the Innovation Union (Europe 2020) flagship initiative .

Health Theme Objectives


The Health Theme: Structure

Activity 1:Biotechnology, generic tools & technologies for health

Activity 2:Translating research for

human health

Activity 3:Optimising the delivery of health care

cross-cutting issues: international cooperation, SMEs, child health, ageing populations, gender-related health issues

Activity 4: Support actions & response to policy needs

The Innovative Medicines Initiative


Health Theme Funding 2007 - 2013

YearTotal

FundingProjects Funded

2007€641

million153

2008€577

million172

2009€611

million105

2010€621

million131

2011€650

million~126

2012€620

million?

2013€780

million?


UK Performance (Health Theme)

Health Funding totals 2007 -2009 – All Participations


UK FP7 Health Theme in Numbers*Submissions with UK partners = 3264*Successful projects with UK partners = 859

UK coordinated submissions = 38393 projects coordinated by UK partners

*2007 – 2009 data – from GAs and participants database (released on 1 May 2010 - data cut-off date 25 March 2010

52 UK SMEs in active FP7 projects (plus 17 new 2010)


SME Participation

EU target of 15% funding to SME partners


Access significant research funding• 75% RTD costs and 100% management and training costs• EU contribution between €2 and 12 million• Overhead rate for HEIs and SMEs = 60%

Strengthening Research Capabilities• Increased collaboration between basic and clinical researchers,

regulatory bodies and patient groups

Access to new networks and contacts• develop new business contacts from the linkages formed in a

consortium• Access to IP and facilities otherwise unavailable

Elevated Profile• Publications, CORDIS

Collaborative Research: Why?


Collaborative Research: Who?

Countries•EU Member States – broadest rights and access•Associated Countries – e.g. Iceland, Norway, Turkey, Israel•International Cooperation Partner Countries (ICPC) – e.g. Russia, Central Asian, Balkan, North African countries•Industrialised high-income countries (e.g Australia, Korea, Japan) – self financing. USA has reciprocal arrangement•Co-operation with “third countries” explicitly encouraged in FP7

Organisations•research groups at universities or research institutes•innovative companies (SMEs and larger)•public or governmental administration (eg NHS trusts) •Charities and other not for profit organisations


• Build consortium :– 3 legal entities from minimum of 3 EU Member states or

Associated Countries– Other partners added per requirements of

project/partner mix – Some other special eligibility criteria may apply – read

call document carefully

• Match project with the topic– Seek advice if not sure– Funding level is indicative of project scope – Pay attention to expected outcome – European scope

• Follow rules for submission (EPSS)

Collaborative Research: How?


WP First Draft Open day

(Brussels) 09 June 2011

Call published

Stage 1 Deadline

NCP Roadshow

Evaluation results

Evaluation

PC Meetings

Collaborative Research: When?


Framework Programme 7Support and Further Information



Initial Considerations

Are you ready for participation?– Does it fit your aspirations/business plan– Collaborative projects mean working alongside international

partners. • Does this suit you way of working?• Can you pull together or find a consortium?

– Funding is highly competitive, prepare to be disappointed– Do you want to lead a project? (Time/resource)– Is the level of funding appropriate?– Can you wait 1 year for the money?


Key Tips

• Competition is fierce – must be well over the threshold to succeed

• Remember the European aspect• Read the call carefully – seek 2nd and 3rd opinions on

topic fit• Write simply and clearly – don’t assume expert

knowledge• Make time to do a good job – avoid last minute

submissions• Seek help early on


Support and Further Information


• Informing and Awareness Raising– Call documents and supporting information– Website and printed newsletters, e-bulletins– Promotional activities – info days, seminars, – Signposting – other themes + funding schemes

• Advising and Training– Helpline – e-mail and telephone enquiries– Partner search– Direct support

• Feedback and Signposting– Problems or difficulties during implementation or participation– Direct contact with EU Scientific Officers– Identifying and communicating other areas of support and funding

NCP Support

All advice is impartial, confidential and free


Support and Further Information

Website https://ktn.innovateuk.org/web/fp7uk

E mail [email protected]

Phone 01302 322633

Mobile 07775 584028

Alternative

[email protected]

+44 (0)20 7395 2205


Framework Programme 72012 Call Information



2012 Call – Context

Innovation Union•research and innovation are key drivers of competitiveness, jobs, sustainable growth and social progress.

•More topics targeting knowledge generation to deliver innovative products, processes and services.

•Challenge led programme focusing on specific issues

•More emphasis on exploitation issues such as dissemination, IP protection and knowledge generation.


2012 Call – Innovation Driven

• Challenge driven – fewer areas open, multiple projects in each area. (36 topics total)– Primary focus is European Innovation Partnership initiative on

active and healthy ageing– Aim to mobilise critical mass of resources and implement

coherent set of actions – Interlinked topics to bring in wide range of inputs

• Balance upstream research and activities closer to market to achieve short and medium-term outcomes– focus on medical technologies– address the socio-economic challenge of innovation


2012 Call – Closed Areas

1.1 High Throughput Research

1.3 Suitability, Safety and Efficacy of Therapies*2.2.1 Brain and Brain Related Diseases

2.3.1 Anti Microbial Drug Resistance

2.3.3 Potentially New and Re-emerging Epidemics

2.3.4 Neglected Infectious Diseases*

2.4.1 Cancer

2.4.2 Cardiovascular Disease

3.1 Translating the Results of Clinical Research Outcome

3.3 Health Promotion and Prevention

4.2 Responding to EU Policy Needs


2012 Call Overview

• SME Focus – many SME targeted topics and new SME Call

• Active and Healthy Ageing – 9 coordinated topics

• Medical Technologies – feature highly (related to SME focus)

• Other areas of focus:Rare Diseases

Clinical Trials

Personalised and Regenerative Medicine (inc transplantation)

Systems Biology and -omics

HIV/AIDS, Malaria and TB

Healthcare delivery

Coordination and Support Activities


2012 Call – SME Focused

• Two stage submission/evaluation • Several funded proposals per topic• Technology/Methods based topics• Open topic descriptions• Small – medium sized projects

– €3m or €6m EC contribution– 2 – 5 year duration

• SME targeted topics– 10 Minimum 30% of EC contribution to SMEs– 6 Minimum 15% of EC contribution to SMEs

> 30%

>15%


Health Theme Funding 2007 - 2013

YearTotal

FundingProjects Funded

SME Targeted

2 Stage

2007€641

million153 0% 0

2008€577

million172 0% 0

2009€611

million105 0% 0

2010€621

million131 0% 19%

2011€650

million~126 20% 75%

2012€620

million? 53% 100%

2013€780

million? ~ 50% 100%


2012 Call – Pilot SME Innovation Call

• 3 topics only:– 1,4-2: Medical Technology for transplantation and bioartificial organs

– 2.3.0-1: Diagnostics for infectious diseases in humans

– 2.4.5-1: Technological approaches to combating sensory impairments

• SMEs have leading role in the project• >50% EU funding goes to SME partners• # participants limited (3 – 5)• All partners from EU MS or ACs • Limits on project duration • Accelerated evaluation and grant negotiation timeline

> 50%


2012 Call – Research Priorities#1 Ageing

Must meet Europe 2020 objectives of active and healthy ageing:

– Healthy, active and independent lives until old age– Ensure the sustainability and efficiency of social and healthcare systems– Create a European/Global market for innovative products and services related to

healthy and active ageing

11 Topics in call are linked to EIP initiative

Cross thematic initiative: ICT,KBBE + SSH

EIP


2012 Call – Research Priorities#2 Medical Technologies

• Supporting the “innovation” strategy and closer to market approach

• Large overlap with “SME friendly” topics

• 9 topics through the work programme Tech


2012 Call – Research Priorities#3 Clinical Trials

•Continue the initiative started in the 2011 call for investigator driven clinical trials

– Improve quality of clinical trials data in Europe

– Strengthen CTs in Europe in areas with unmet medical needs

•Funding for Stage II,III or IV clinical trials as RTD activities (i.e. 75% EC contribution). Flexibility w.r.t. duration and participation.•Involvement of patient groups encouraged•Outsourcing possible

– Subcontracted third party– Reimbursement on cost basis

Clin


1.2: Detection, Diagnosis and Monitoring

1.2.1Development of technologies with a view to patient group stratification for personalised medicine applications

6,000,000 >1

EIP

> 30%

• Support R&D and/or proof of principle of technologies for application in the area of personalised medicines

• Tailored medical interventions• More effective• Fewer undesirable side effects

• Technologies should be of use for research, screening, diagnostics and/or guidance on therapeutic interventions


1.4: Innovative Therapeutic Approaches and Interventions

1.4-1 Innovative approaches to solid organ transplantation 6,000,000 >1

1.4-2 Medical technology for the transplantation sector and bioartificial organs 6,000,000 >1

1.4-3* Innovative strategies for translation of stem cell based therapies in regenerative medicine 6,000,000 1

1.4-4 Targeted nucleic acid delivery as an innovative therapeutic or prophylactic approach 6,000,000 >1

>15%

>15%

EIP

> 50%

> 30%

Tech

Tech

* 1.4-3 requires cooperation with Australia

Clin

Transplantation topics have not featured highly in FP7 to date


2.1.1: Large Scale Data Gathering

2.1.1.1-A Support for international rare disease research 2,000,000 1

2.1.1.1-B Clinical utility of -omics for better diagnosis of rare diseases 12,000,000 2

2.1.1.1-C Databases, biobanks and clinical bio-informatics' hub for rare diseases 12,000,000 1

2.1.1-2 Validation of -omics based biomarkers for diseases affecting the elderly 12,000,000 >1

2.1.1-3 Statistical methods for collection and analysis of -omics data 6,000,000 >1 >15%

EIP

> 30%

> 30%

• Objective is to use high-throughput technologies to generate data for elucidating the function of genes and gene products.

• Topics focus on the clinical use of –omics approaches and analysis of their outcomes.


2.1.2: Systems Biology

• medical needs should drive systems biology research• using systems medicine to improve understanding of disease

mechanisms, prognosis and diagnosis of common diseases• Coordinate European research activities for systems biology

applications to medicine

2.1.2-1 Systems medicine: SME-driven research applying systems biology approaches to address clinical needs 3,000,000 >1

2.1.2-2Systems medicine: Applying systems biology approaches for understanding common human diseases and their co-morbidities

12,000,000 >1

2.1.2-3 Preparing for the future research and innovation activities in systems medicine 3,000,000 1

> 30%


2.2.2: Human Development and Ageing

2.2.2-1Integrative systems biology and comparative genomics for studying human ageing and most common age-related conditions

6,000,000 >1

2.2.2-2Investigator-driven clinical trials for optimisation of treatment for elderly patients with multiple diseases

6,000,000 >1>15%

EIP

EIP

Clin

> 30%

• Focus on use and application of –omics knowledge and tools to gain a clear understanding of the fundamental mechanisms of human ageing

• Clinical trials should compare outcomes of various treatment regimens


2.3.0: Cross Cutting

2.3.0-1 Diagnostics for infectious diseases in humans 6,000,000 >1

2.3.0-2 ERA-NET on Infectious Diseases 2,000,000 1

> 50%

Tech

• SMEs should take a leading role in 2.3.0-1• Project should be < 3 years • €6,000,000 ceiling is max only

• ERA-NET should deepen and extend the coordination of European research in infectious diseases and be complementary to other European activities in this area.


2.3.2: HIV/AIDS Malaria and TB

• Co-infection and co-morbidity of HIV and other common infectious diseases poorly understood

• Prevention topic is looking for small, rapid projects o 1 – 3 years, €1 – 6 million funding

• Low cost interventions looking for solutions that can be implemented within the project period

2.3.2-1 Co-infection and co-morbidity in HIV/AIDS, malaria, tuberculosis and/or hepatitis 6,000,000 >1

2.3.2-2 Co-morbidity between infectious and non-communicable diseases 6,000,000 >1

2.3.2-3 Prevention and treatment for HIV/AIDS, malaria and tuberculosis 6,000,000 >1

2.3.2-4 Low-cost interventions for disease control in resource poor settings 3,000,000 >1

>15%


2.4.3: Diabetes and Obesity

2.4.3-1 Innovative approach to manage diabetes 6,000,000 >1

2.4.3-2 Investigator-driven clinical trials for type 1 diabetes research 6,000,000 >1

Clin

> 30%

Tech


2.4.4: Rare Diseases

2.4.4-1Preclinical and/or clinical development of substances with a clear potential as orphan drugs

6,000,000 >1

2.4.4-2 Observational trials in rare diseases 3,000,000 >1

2.4.4-3 Best practice and knowledge sharing in the clinical management of rare diseases 2,000,000 1

Clin

Clin

> 30%


2.4.5: Other Chronic Diseases

2.4.5-1 Technological approaches to to combating sensory impairments 6,000,000 >1

2.4.5-2 Biomarkers and diagnostics for chronic inflammatory diseases of the joints 6,000,000 >1

EIP

> 50%

>15%

EIP

Tech

Tech


2012 Call – Healthcare Delivery

• Addressing the need for systematic mapping of variations in health care practice and standardisation of health technology assessment

• Various areas of healthcare covered• EU has strong political stance on healthcare equality

3.2-1 Improving the organisation of health service delivery 3,000,000 >1

3.2-2 New methodologies for health technology assessment 3,000,000 >1

3.2-2 Social Innovation platform for ageing research 6,000,000 1

3.4-1 Health systems/services research in low and middle income countries 6,000,000 >1

EIP

EIP

Tech


2012 Call – Coordination and Support Actions

• Various actions to complement research activities, develop infrastructure and determine future activities

4.1-1Network to encourage technology transfer in FP-funded health research (especially in academic and governmental organisations)

2,000,000 1

4.1-2 Training actions linked to intellectual property rights management and technology transfer 2,000,000 1

4.1-3Support for Presidency events: Organisation of supporting actions and events related to the Presidency of the European Union

100,000 >1

4.1-4 Communicating the benefits of European research to the general public 1,000,000 >1

4.1-5 Preparing for the future for health research and innovation 500,000 >1


09 June 2011: Open Info Day, Brussels

10 June 2011: Brokerage Event, Brussels

20 July 2011: Call Opens – EPSS available

27 Sept 2011: likely Stage 1 deadline (INNOVATION 2)

04 Oct 2011: likely Stage 1 deadline (INNOVATION 1)

Dec 2011: Stage 1 notification

Feb 2012: Stage 2 deadline

Key Dates


Other Health Related EU Funding Sources 2011

Nanosciences, Materials and Production NMP

NMP.2012.1.2-2: Development and phase-I clinical trials of novel therapeutic nanotechnology-enabled systems for the diagnosis and treatment of atherosclerosis

NMP.2012.2.2-1: Biomaterials for improved performance of medical implants

Likely timeframe similar to Health call


Other Health Related EU Funding Sources 2011

ICT call•Virtual Physiological Human•E-health and data management

KBBE call

Research For the Benefit of SMEs •Call opens July 2011

Ambient Assisted Living•ICT based solutions for Advancement of Older Persons’ Mobility•Call opened 31 March 2011, deadline 30 June 2011

graham hughes - beta technology - fp 7 call presentation

Technology

health theme funding

health industry

health theme objectives

uk partners

basic research

human health activity

global health issues

health of european citizens